Roanna Ruiz
Stock Analyst at Leerink Partners
(0.72)
# 3,778
Out of 4,835 analysts
63
Total ratings
30.77%
Success rate
-21.89%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $2.61 | +168.20% | 1 | Apr 28, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $4.88 | +22.95% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $12.28 | +46.58% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $0.54 | +86.85% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $4.60 | +334.78% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $13.60 | +98.53% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $2.38 | +446.22% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $3.88 | +260.82% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $305.35 | +8.07% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $31.00 | +87.10% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $75.08 | -66.70% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $5.76 | +751.43% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $3.22 | +303.73% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $2.75 | +118.58% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.90 | +0.53% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $81.24 | +47.71% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $5.84 | +756.16% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $10.58 | +278.07% | 6 | Oct 19, 2022 |
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $2.61
Upside: +168.20%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.88
Upside: +22.95%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $12.28
Upside: +46.58%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.54
Upside: +86.85%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $4.60
Upside: +334.78%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $13.60
Upside: +98.53%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $2.38
Upside: +446.22%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $3.88
Upside: +260.82%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $305.35
Upside: +8.07%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $31.00
Upside: +87.10%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $75.08
Upside: -66.70%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $5.76
Upside: +751.43%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $3.22
Upside: +303.73%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $2.75
Upside: +118.58%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $18.90
Upside: +0.53%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $81.24
Upside: +47.71%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $5.84
Upside: +756.16%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $10.58
Upside: +278.07%